

# Analysis of the Appropriateness of Tafamidis Prescription for the Treatment of Patients with Transthyretin Cardiac Amyloidosis

Gallego Hernández G, López-González AM, Albarrán Gómez A, Eiros Bachiller R, Villacorta Argüelles E, Gallego Delgado M, Martín Cillero T, Sánchez Fernández PL, Otero MJ.

1. Servicio de Farmacia. 2. Servicio de Cardiología. Hospital Universitario de Salamanca

## Background and Importance

Tafamidis 61 mg has recently been authorized in Spain to treat the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), considering the results of the ATTR-ACT trial.

## Objective

To analyze the initial prescriptions of **tafamidis** in patients with ATTR-CM.

## Materials and Methods

Observational, descriptive, and prospective study (September 2023- September 2024) of tafamidis prescriptions in a university hospital with a pharmaceutical validation.



### Patients included

- Diagnosis: ATTR-CM
- Treatment request: tafamidis 61 mg
- Adherence to all criteria of the national health system.

### Other recommendations not to start treatment



- Glomerular filtration rate (GFR) <25 mL/min/1,73 m<sup>2</sup>
- Transaminase values >2 times the upper limit of normal (ULN)

## Results






FIG 1. TYPE OF DIAGNOSIS



■ Hereditary ATTR-CM ■ Wild-type ATTR-CM

FIG 2. NYHA CLASS



■ II ■ III

Table 1. Baseline characteristics of the patients

Mean left ventricular ejection fraction (LVEF)	56% (SD: ±8)
Median NT-proBNP	2,243 pg/mL [IQR 1,809–5,015]
Mean interventricular septum wall thickness	15 mm (SD: ±3)
6-minute walk test	273 m (SD: ±122)
Mean GFR	51 mL/min/1.73 m <sup>2</sup> (SD: ±18)

## Conclusion and Relevance

- The majority of tafamidis 61 mg prescriptions in patients with ATTR-CM met the criteria established by de national health system.
- Discrepancies during pharmaceutical treatment review were resolved by consensus among the multidisciplinary team members at the center.